![]() |
||||||
![]() |
FOCUSED ULTRASOUND SURGERY FOUNDATION |
NEWSLETTER VOL. 23 | ||||
|
![]() |
||
![]() |
Dear Reader According to the World Health Organization, an estimated 900,000 new cases of prostate cancer are diagnosed globally each year. More prevalent in developed countries, the disease afflicts Americans at the highest rate of all. Thanks to the widespread use of PSA testing, early detection and treatment of prostate cancer has become commonplace, and the ranks of long-term survivors are growing. Unfortunately, there is a downside to these advances: today's most widely used therapies destroy both prostate tumors and surrounding nerve bundles, causing incontinency and impotency in many patients. The long-sought solution to this "survive but don't thrive" dilemma may lie in noninvasive focused ultrasound and its ability to precisely target and destroy diseased tissue without damaging adjacent structures. So far, ultrasound-guided focused ultrasound treatments - which are only available outside the U.S. - are proving effective and non-debilitating. Many believe that even better outcomes will be achieved by focused ultrasound procedures performed under MR-guidance. As reported in this issue, the first human clinical trial evaluating MR-guided focused ultrasound as a therapy for prostate cancer is underway, with seven patients treated to date. This is an exciting development for the field of MR-guided focused ultrasound and for prostate cancer patients worldwide. Stay tuned for study updates in future issues of this newsletter. Before closing, it's important to note that prostate cancer will be a key topic at next month's 2nd International Symposium on MR-guided Focused Ultrasound. Leading researchers and clinicians will report the latest progress on many fronts, including prostate cancer. Within coming weeks, a list of presentations and abstracts will be posted on the Foundation website. |
![]() |
|||
Important symposium reminder: Deadline for discounted hotel reservations is September 27 | |||
![]() |
|
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||
Abstract submissions exceed expectations, indicate where R&D is most robust | ||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|||
Foundation will announce Young Investigator Award winners this month | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Foundation exclusive: MR-guided focused ultrasound projects, investigators and sites on our website | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Donor designates $100K to R&D for new prostate treatments | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
UCSF receives NIH grant to purchase MR-guided FUS system | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
First prostate cancer patients treated with MR-guided focused ultrasound | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Start-up firm, FUS Instruments, offers turnkey system for preclinical research | |||
![]() |
|
![]() |
|
![]() |
![]() |
![]() |